Business Context and Reporting Period
Company: Immunic, Inc. (IMUX)
Filing Type: Form 10-Q (Unaudited)
Period Ended: June 30, 2026
Business Overview: Immunic is a late-stage biotechnology company developing novel oral therapies for neurologic diseases. Its lead candidate, vidofludimus calcium (IMU-838), is in Phase 3 clinical development for relapsing multiple sclerosis (MS) with a planned Phase 3 trial for progressive MS. The company has no approved products and has not generated product revenue.
Key Financial Metrics
| Metric (in thousands) | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(66,687) | $(52,293) |
| Net Loss Per Share (Basic & Diluted) | $(1.83) | $(4.48) |
| Operating Expenses | $68,562 | $53,908 |
| Research & Development (R&D) | $51,557 | $42,902 |
| General & Administrative (G&A) | $17,005 | $11,006 |
| Cash and Cash Equivalents (End of Period) | $155,098 | $55,310 |
| Net Cash Used in Operating Activities | $(48,299) | $(46,385) |
| Net Cash Provided by Financing Activities | $188,760 | $65,518 |
| Accumulated Deficit | $(675,258) | $(563,692) |
Material Changes vs. Prior Period
- Liquidity Surge: Cash and cash equivalents increased from $15.5 million (Dec 31, 2025) to $155.1 million (June 30, 2026), driven primarily by a $187.3 million net proceeds from a February 2026 Private Placement.
- Expense Growth: Total operating expenses increased 27% year-over-year to $68.6 million. R&D expenses rose 20% due to increased personnel costs (including $3.8 million in stock-based compensation) and drug supply costs, partially offset by decreases in specific clinical trial costs (CALLIPER and ENSURE).
- Stock-Based Compensation: Total stock-based compensation expense increased significantly to $11.2 million for the six months ended June 30, 2026, compared to $3.9 million in the prior year period, reflecting new grants and reclassifications.
- Reverse Stock Split: A 1-for-10 reverse stock split became effective on April 27, 2026. All share and per-share data in this report have been restated to reflect this split.
Guidance, Outlook, and Management Commentary
- Clinical Milestones: Top-line data for the Phase 3 ENSURE trials (relapsing MS) is expected by the end of 2026. If positive, the company intends to file a New Drug Application (NDA) in mid-2027, targeting U.S. regulatory approval in 2028. A Phase 3 trial for progressive MS is expected to initiate later in 2026.
- Liquidity Outlook: Management expects the current cash balance of $155.1 million to fund operations beyond twelve months from the filing date.
- Capital Resources: The company has an active At-The-Market (ATM) facility with $80.0 million in remaining capacity and a shelf registration allowing for up to $262.2 million in additional offerings.
- Leadership Changes: Erik Lundgren was appointed CEO effective June 1, 2026, succeeding Daniel Vitt. Michael Panzara was appointed Chief Medical Officer in April 2026. Several board appointments and resignations occurred during the period.
- Risks: The company faces risks related to clinical trial outcomes, regulatory approval, and the need for substantial additional funding. It has incurred operating losses since inception and expects to continue doing so.
Investor Verification Checklist
- Capital Runway: Verify the sufficiency of the $155.1 million cash balance against projected burn rates for the remainder of 2026 and 2027, particularly given the upcoming NDA filing costs.
- Warrant Dilution: Review the terms of the 22.9 million pre-funded warrants and common warrants issued in the February 2026 offering, noting the exercise price of $8.73 and the potential for significant dilution upon exercise.
- Royalty Obligations: Confirm the impact of the 5% synthetic royalty on future sales of vidofludimus calcium granted to Series B warrant holders in exchange for 5.1 million warrants.
- Stock-Based Compensation: Assess the sustainability of the elevated stock-based compensation expense ($11.2M in H1 2026) and its impact on future cash flow and dilution.
- Clinical Data Timing: Monitor the timeline for the ENSURE trial top-line data (expected end of 2026) as a critical binary event for valuation and future financing needs.